nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—SLC22A3—Melphalan—ovarian cancer	0.507	0.909	CbGbCtD
Procainamide—CYP2D6—Vinorelbine—ovarian cancer	0.0368	0.0659	CbGbCtD
Procainamide—CYP2D6—Doxorubicin—ovarian cancer	0.0139	0.025	CbGbCtD
Procainamide—BCHE—diaphragm—ovarian cancer	0.0127	0.0977	CbGeAlD
Procainamide—Lucanthone—TOP1—ovarian cancer	0.00701	0.61	CrCbGaD
Procainamide—SCN7A—myometrium—ovarian cancer	0.00503	0.0387	CbGeAlD
Procainamide—DNMT1—Vinblastine—Vinorelbine—ovarian cancer	0.005	1	CbGdCrCtD
Procainamide—DNMT1—myometrium—ovarian cancer	0.00386	0.0298	CbGeAlD
Procainamide—DNMT1—embryo—ovarian cancer	0.00372	0.0286	CbGeAlD
Procainamide—DNMT1—epithelium—ovarian cancer	0.00303	0.0234	CbGeAlD
Procainamide—DNMT1—uterine cervix—ovarian cancer	0.00301	0.0232	CbGeAlD
Procainamide—SCN7A—female reproductive system—ovarian cancer	0.00293	0.0226	CbGeAlD
Procainamide—DNMT1—decidua—ovarian cancer	0.00287	0.0221	CbGeAlD
Procainamide—DNMT1—endometrium—ovarian cancer	0.00272	0.0209	CbGeAlD
Procainamide—SCN7A—female gonad—ovarian cancer	0.00267	0.0206	CbGeAlD
Procainamide—DNMT1—gonad—ovarian cancer	0.00252	0.0194	CbGeAlD
Procainamide—DNMT1—uterus—ovarian cancer	0.00251	0.0193	CbGeAlD
Procainamide—SLC22A4—myometrium—ovarian cancer	0.00239	0.0184	CbGeAlD
Procainamide—SCN7A—testis—ovarian cancer	0.00237	0.0182	CbGeAlD
Procainamide—DNMT1—female reproductive system—ovarian cancer	0.00225	0.0174	CbGeAlD
Procainamide—SLC22A3—myometrium—ovarian cancer	0.00218	0.0168	CbGeAlD
Procainamide—DNMT1—bone marrow—ovarian cancer	0.00213	0.0164	CbGeAlD
Procainamide—SCN8A—testis—ovarian cancer	0.00211	0.0162	CbGeAlD
Procainamide—SLC22A3—embryo—ovarian cancer	0.0021	0.0161	CbGeAlD
Procainamide—DNMT1—female gonad—ovarian cancer	0.00205	0.0158	CbGeAlD
Procainamide—DNMT1—vagina—ovarian cancer	0.00204	0.0157	CbGeAlD
Procainamide—SCN3A—decidua—ovarian cancer	0.00203	0.0156	CbGeAlD
Procainamide—Sunitinib—CHEK2—ovarian cancer	0.002	0.174	CrCbGaD
Procainamide—SCN9A—testis—ovarian cancer	0.00185	0.0143	CbGeAlD
Procainamide—DNMT1—testis—ovarian cancer	0.00182	0.014	CbGeAlD
Procainamide—SLC22A4—decidua—ovarian cancer	0.00177	0.0137	CbGeAlD
Procainamide—SCN7A—lymph node—ovarian cancer	0.00172	0.0132	CbGeAlD
Procainamide—SLC22A3—uterine cervix—ovarian cancer	0.0017	0.0131	CbGeAlD
Procainamide—SLC22A4—endometrium—ovarian cancer	0.00168	0.013	CbGeAlD
Procainamide—SCN4A—testis—ovarian cancer	0.00165	0.0127	CbGeAlD
Procainamide—SCN2A—vagina—ovarian cancer	0.00164	0.0126	CbGeAlD
Procainamide—SCN3A—female reproductive system—ovarian cancer	0.00159	0.0123	CbGeAlD
Procainamide—SLC22A5—myometrium—ovarian cancer	0.00158	0.0122	CbGeAlD
Procainamide—BCHE—myometrium—ovarian cancer	0.00154	0.0119	CbGeAlD
Procainamide—SLC22A3—endometrium—ovarian cancer	0.00153	0.0118	CbGeAlD
Procainamide—SCN3A—bone marrow—ovarian cancer	0.0015	0.0116	CbGeAlD
Procainamide—ACHE—testis—ovarian cancer	0.00148	0.0114	CbGeAlD
Procainamide—SCN3A—vagina—ovarian cancer	0.00144	0.0111	CbGeAlD
Procainamide—SCN5A—vagina—ovarian cancer	0.00144	0.0111	CbGeAlD
Procainamide—SLC22A3—gonad—ovarian cancer	0.00142	0.011	CbGeAlD
Procainamide—SLC22A4—female reproductive system—ovarian cancer	0.0014	0.0107	CbGeAlD
Procainamide—SCN9A—lymph node—ovarian cancer	0.00134	0.0103	CbGeAlD
Procainamide—DNMT1—lymph node—ovarian cancer	0.00132	0.0102	CbGeAlD
Procainamide—SLC22A4—bone marrow—ovarian cancer	0.00132	0.0101	CbGeAlD
Procainamide—SCN3A—testis—ovarian cancer	0.00129	0.00991	CbGeAlD
Procainamide—SLC22A3—female reproductive system—ovarian cancer	0.00127	0.00978	CbGeAlD
Procainamide—SLC22A4—vagina—ovarian cancer	0.00126	0.00972	CbGeAlD
Procainamide—SLC22A5—uterine cervix—ovarian cancer	0.00123	0.00949	CbGeAlD
Procainamide—SLC22A1—vagina—ovarian cancer	0.0012	0.00926	CbGeAlD
Procainamide—BCHE—uterine cervix—ovarian cancer	0.0012	0.00925	CbGeAlD
Procainamide—SLC22A3—female gonad—ovarian cancer	0.00116	0.0089	CbGeAlD
Procainamide—SLC22A3—vagina—ovarian cancer	0.00115	0.00885	CbGeAlD
Procainamide—Oliguria—Docetaxel—ovarian cancer	0.00114	0.00566	CcSEcCtD
Procainamide—Rash maculo-papular—Paclitaxel—ovarian cancer	0.00113	0.0056	CcSEcCtD
Procainamide—SLC22A5—endometrium—ovarian cancer	0.00111	0.00859	CbGeAlD
Procainamide—Lightheadedness—Paclitaxel—ovarian cancer	0.00111	0.00551	CcSEcCtD
Procainamide—BCHE—endometrium—ovarian cancer	0.00109	0.00836	CbGeAlD
Procainamide—Neutropenia—Vinorelbine—ovarian cancer	0.00108	0.00537	CcSEcCtD
Procainamide—ACHE—lymph node—ovarian cancer	0.00107	0.00825	CbGeAlD
Procainamide—SLC22A3—testis—ovarian cancer	0.00103	0.00789	CbGeAlD
Procainamide—SCN10A—lymph node—ovarian cancer	0.00102	0.00788	CbGeAlD
Procainamide—Hepatomegaly—Epirubicin—ovarian cancer	0.001	0.00497	CcSEcCtD
Procainamide—BCHE—uterus—ovarian cancer	0.001	0.00771	CbGeAlD
Procainamide—Flushing—Melphalan—ovarian cancer	0.000986	0.00488	CcSEcCtD
Procainamide—Lidocaine—EGFR—ovarian cancer	0.000975	0.0848	CrCbGaD
Procainamide—Chills—Topotecan—ovarian cancer	0.000974	0.00482	CcSEcCtD
Procainamide—Angioedema—Chlorambucil—ovarian cancer	0.00097	0.0048	CcSEcCtD
Procainamide—Agranulocytosis—Vinorelbine—ovarian cancer	0.000965	0.00478	CcSEcCtD
Procainamide—Atrial fibrillation—Paclitaxel—ovarian cancer	0.000953	0.00472	CcSEcCtD
Procainamide—Renal impairment—Paclitaxel—ovarian cancer	0.000949	0.0047	CcSEcCtD
Procainamide—Lightheadedness—Docetaxel—ovarian cancer	0.000943	0.00467	CcSEcCtD
Procainamide—SCN3A—lymph node—ovarian cancer	0.000933	0.00718	CbGeAlD
Procainamide—Hepatomegaly—Doxorubicin—ovarian cancer	0.00093	0.0046	CcSEcCtD
Procainamide—Pleural effusion—Epirubicin—ovarian cancer	0.000929	0.0046	CcSEcCtD
Procainamide—Cardiac failure—Paclitaxel—ovarian cancer	0.000925	0.00458	CcSEcCtD
Procainamide—SLC22A5—female reproductive system—ovarian cancer	0.000924	0.00711	CbGeAlD
Procainamide—Lethargy—Paclitaxel—ovarian cancer	0.000921	0.00456	CcSEcCtD
Procainamide—Convulsion—Chlorambucil—ovarian cancer	0.00092	0.00455	CcSEcCtD
Procainamide—BCHE—female reproductive system—ovarian cancer	0.0009	0.00693	CbGeAlD
Procainamide—Ill-defined disorder—Topotecan—ovarian cancer	0.000877	0.00434	CcSEcCtD
Procainamide—Confusional state—Chlorambucil—ovarian cancer	0.000873	0.00433	CcSEcCtD
Procainamide—Angioedema—Topotecan—ovarian cancer	0.000863	0.00428	CcSEcCtD
Procainamide—Cardiac disorder—Vinorelbine—ovarian cancer	0.000862	0.00427	CcSEcCtD
Procainamide—Flushing—Vinorelbine—ovarian cancer	0.000862	0.00427	CcSEcCtD
Procainamide—Pleural effusion—Doxorubicin—ovarian cancer	0.000859	0.00425	CcSEcCtD
Procainamide—Cardiac arrest—Paclitaxel—ovarian cancer	0.000858	0.00425	CcSEcCtD
Procainamide—Malaise—Topotecan—ovarian cancer	0.000852	0.00422	CcSEcCtD
Procainamide—Hepatic failure—Docetaxel—ovarian cancer	0.000852	0.00422	CcSEcCtD
Procainamide—BCHE—bone marrow—ovarian cancer	0.000849	0.00654	CbGeAlD
Procainamide—Thrombocytopenia—Chlorambucil—ovarian cancer	0.000848	0.0042	CcSEcCtD
Procainamide—SLC22A5—female gonad—ovarian cancer	0.00084	0.00647	CbGeAlD
Procainamide—SLC22A5—vagina—ovarian cancer	0.000835	0.00643	CbGeAlD
Procainamide—Anorexia—Chlorambucil—ovarian cancer	0.000826	0.00409	CcSEcCtD
Procainamide—Abdominal pain upper—Paclitaxel—ovarian cancer	0.000825	0.00408	CcSEcCtD
Procainamide—SLC22A4—lymph node—ovarian cancer	0.000817	0.00629	CbGeAlD
Procainamide—BCHE—vagina—ovarian cancer	0.000814	0.00627	CbGeAlD
Procainamide—Atrial fibrillation—Docetaxel—ovarian cancer	0.000808	0.004	CcSEcCtD
Procainamide—Myalgia—Topotecan—ovarian cancer	0.000804	0.00398	CcSEcCtD
Procainamide—Arthralgia—Topotecan—ovarian cancer	0.000804	0.00398	CcSEcCtD
Procainamide—Renal impairment—Docetaxel—ovarian cancer	0.000804	0.00398	CcSEcCtD
Procainamide—Convulsion—Melphalan—ovarian cancer	0.000802	0.00397	CcSEcCtD
Procainamide—Discomfort—Topotecan—ovarian cancer	0.000795	0.00394	CcSEcCtD
Procainamide—Myalgia—Melphalan—ovarian cancer	0.000788	0.0039	CcSEcCtD
Procainamide—Cardiac failure—Docetaxel—ovarian cancer	0.000784	0.00388	CcSEcCtD
Procainamide—Lethargy—Docetaxel—ovarian cancer	0.000781	0.00387	CcSEcCtD
Procainamide—Oliguria—Epirubicin—ovarian cancer	0.000772	0.00382	CcSEcCtD
Procainamide—Thrombocytopenia—Topotecan—ovarian cancer	0.000755	0.00374	CcSEcCtD
Procainamide—Decreased appetite—Chlorambucil—ovarian cancer	0.000753	0.00373	CcSEcCtD
Procainamide—Ill-defined disorder—Vinorelbine—ovarian cancer	0.00075	0.00371	CcSEcCtD
Procainamide—SLC22A5—testis—ovarian cancer	0.000745	0.00574	CbGeAlD
Procainamide—SLC22A3—lymph node—ovarian cancer	0.000743	0.00572	CbGeAlD
Procainamide—Thrombocytopenia—Melphalan—ovarian cancer	0.000739	0.00366	CcSEcCtD
Procainamide—Angioedema—Vinorelbine—ovarian cancer	0.000739	0.00366	CcSEcCtD
Procainamide—Anorexia—Topotecan—ovarian cancer	0.000735	0.00364	CcSEcCtD
Procainamide—Neutropenia—Paclitaxel—ovarian cancer	0.00073	0.00361	CcSEcCtD
Procainamide—Malaise—Vinorelbine—ovarian cancer	0.000729	0.00361	CcSEcCtD
Procainamide—BCHE—testis—ovarian cancer	0.000726	0.00559	CbGeAlD
Procainamide—Anorexia—Melphalan—ovarian cancer	0.00072	0.00356	CcSEcCtD
Procainamide—Oliguria—Doxorubicin—ovarian cancer	0.000714	0.00354	CcSEcCtD
Procainamide—Feeling abnormal—Chlorambucil—ovarian cancer	0.000714	0.00353	CcSEcCtD
Procainamide—Ventricular tachycardia—Epirubicin—ovarian cancer	0.000711	0.00352	CcSEcCtD
Procainamide—Gastrointestinal pain—Chlorambucil—ovarian cancer	0.000708	0.00351	CcSEcCtD
Procainamide—Hypotension—Melphalan—ovarian cancer	0.000706	0.00349	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Topotecan—ovarian cancer	0.000703	0.00348	CcSEcCtD
Procainamide—Abdominal pain upper—Docetaxel—ovarian cancer	0.000699	0.00346	CcSEcCtD
Procainamide—Depression—Paclitaxel—ovarian cancer	0.000694	0.00344	CcSEcCtD
Procainamide—Urticaria—Chlorambucil—ovarian cancer	0.000688	0.00341	CcSEcCtD
Procainamide—Arthralgia—Vinorelbine—ovarian cancer	0.000688	0.00341	CcSEcCtD
Procainamide—Myalgia—Vinorelbine—ovarian cancer	0.000688	0.00341	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Melphalan—ovarian cancer	0.000688	0.00341	CcSEcCtD
Procainamide—Abdominal pain—Chlorambucil—ovarian cancer	0.000685	0.00339	CcSEcCtD
Procainamide—Body temperature increased—Chlorambucil—ovarian cancer	0.000685	0.00339	CcSEcCtD
Procainamide—Renal failure—Paclitaxel—ovarian cancer	0.000684	0.00339	CcSEcCtD
Procainamide—Discomfort—Vinorelbine—ovarian cancer	0.00068	0.00337	CcSEcCtD
Procainamide—Decreased appetite—Topotecan—ovarian cancer	0.00067	0.00332	CcSEcCtD
Procainamide—Ventricular tachycardia—Doxorubicin—ovarian cancer	0.000658	0.00326	CcSEcCtD
Procainamide—Decreased appetite—Melphalan—ovarian cancer	0.000656	0.00325	CcSEcCtD
Procainamide—Rash maculo-papular—Epirubicin—ovarian cancer	0.000646	0.0032	CcSEcCtD
Procainamide—Thrombocytopenia—Vinorelbine—ovarian cancer	0.000646	0.0032	CcSEcCtD
Procainamide—Hypersensitivity—Chlorambucil—ovarian cancer	0.000638	0.00316	CcSEcCtD
Procainamide—Bradycardia—Paclitaxel—ovarian cancer	0.000636	0.00315	CcSEcCtD
Procainamide—Feeling abnormal—Topotecan—ovarian cancer	0.000636	0.00315	CcSEcCtD
Procainamide—Gastrointestinal pain—Topotecan—ovarian cancer	0.000631	0.00312	CcSEcCtD
Procainamide—Anorexia—Vinorelbine—ovarian cancer	0.000629	0.00311	CcSEcCtD
Procainamide—Asthenia—Chlorambucil—ovarian cancer	0.000622	0.00308	CcSEcCtD
Procainamide—Neutropenia—Docetaxel—ovarian cancer	0.000618	0.00306	CcSEcCtD
Procainamide—Hypotension—Vinorelbine—ovarian cancer	0.000616	0.00305	CcSEcCtD
Procainamide—Pruritus—Chlorambucil—ovarian cancer	0.000613	0.00303	CcSEcCtD
Procainamide—Urticaria—Topotecan—ovarian cancer	0.000613	0.00303	CcSEcCtD
Procainamide—Body temperature increased—Topotecan—ovarian cancer	0.00061	0.00302	CcSEcCtD
Procainamide—Abdominal pain—Topotecan—ovarian cancer	0.00061	0.00302	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Vinorelbine—ovarian cancer	0.000601	0.00298	CcSEcCtD
Procainamide—Urticaria—Melphalan—ovarian cancer	0.0006	0.00297	CcSEcCtD
Procainamide—Rash maculo-papular—Doxorubicin—ovarian cancer	0.000598	0.00296	CcSEcCtD
Procainamide—CYP2D6—female reproductive system—ovarian cancer	0.000596	0.00459	CbGeAlD
Procainamide—Diarrhoea—Chlorambucil—ovarian cancer	0.000593	0.00294	CcSEcCtD
Procainamide—Renal failure—Docetaxel—ovarian cancer	0.00058	0.00287	CcSEcCtD
Procainamide—Flushing—Paclitaxel—ovarian cancer	0.00058	0.00287	CcSEcCtD
Procainamide—Cardiac disorder—Paclitaxel—ovarian cancer	0.00058	0.00287	CcSEcCtD
Procainamide—Hepatic failure—Epirubicin—ovarian cancer	0.000574	0.00284	CcSEcCtD
Procainamide—Decreased appetite—Vinorelbine—ovarian cancer	0.000573	0.00284	CcSEcCtD
Procainamide—Hypersensitivity—Topotecan—ovarian cancer	0.000568	0.00281	CcSEcCtD
Procainamide—Chills—Paclitaxel—ovarian cancer	0.00056	0.00278	CcSEcCtD
Procainamide—Hypersensitivity—Melphalan—ovarian cancer	0.000556	0.00275	CcSEcCtD
Procainamide—Asthenia—Topotecan—ovarian cancer	0.000553	0.00274	CcSEcCtD
Procainamide—Vomiting—Chlorambucil—ovarian cancer	0.000551	0.00273	CcSEcCtD
Procainamide—Agranulocytosis—Docetaxel—ovarian cancer	0.00055	0.00273	CcSEcCtD
Procainamide—Pruritus—Topotecan—ovarian cancer	0.000546	0.0027	CcSEcCtD
Procainamide—Feeling abnormal—Vinorelbine—ovarian cancer	0.000544	0.00269	CcSEcCtD
Procainamide—Renal impairment—Epirubicin—ovarian cancer	0.000542	0.00269	CcSEcCtD
Procainamide—CYP2D6—female gonad—ovarian cancer	0.000542	0.00418	CbGeAlD
Procainamide—Asthenia—Melphalan—ovarian cancer	0.000542	0.00268	CcSEcCtD
Procainamide—SLC22A5—lymph node—ovarian cancer	0.00054	0.00416	CbGeAlD
Procainamide—Gastrointestinal pain—Vinorelbine—ovarian cancer	0.000539	0.00267	CcSEcCtD
Procainamide—Pruritus—Melphalan—ovarian cancer	0.000534	0.00265	CcSEcCtD
Procainamide—Dysgeusia—Paclitaxel—ovarian cancer	0.000532	0.00264	CcSEcCtD
Procainamide—Hepatic failure—Doxorubicin—ovarian cancer	0.000531	0.00263	CcSEcCtD
Procainamide—Cardiac failure—Epirubicin—ovarian cancer	0.000529	0.00262	CcSEcCtD
Procainamide—Diarrhoea—Topotecan—ovarian cancer	0.000528	0.00261	CcSEcCtD
Procainamide—Lethargy—Epirubicin—ovarian cancer	0.000527	0.00261	CcSEcCtD
Procainamide—BCHE—lymph node—ovarian cancer	0.000526	0.00405	CbGeAlD
Procainamide—Urticaria—Vinorelbine—ovarian cancer	0.000524	0.0026	CcSEcCtD
Procainamide—Abdominal pain—Vinorelbine—ovarian cancer	0.000522	0.00258	CcSEcCtD
Procainamide—Body temperature increased—Vinorelbine—ovarian cancer	0.000522	0.00258	CcSEcCtD
Procainamide—Diarrhoea—Melphalan—ovarian cancer	0.000517	0.00256	CcSEcCtD
Procainamide—Nausea—Chlorambucil—ovarian cancer	0.000515	0.00255	CcSEcCtD
Procainamide—Dizziness—Topotecan—ovarian cancer	0.00051	0.00253	CcSEcCtD
Procainamide—Ill-defined disorder—Paclitaxel—ovarian cancer	0.000504	0.0025	CcSEcCtD
Procainamide—Renal impairment—Doxorubicin—ovarian cancer	0.000502	0.00248	CcSEcCtD
Procainamide—Angioedema—Paclitaxel—ovarian cancer	0.000497	0.00246	CcSEcCtD
Procainamide—Cardiac disorder—Docetaxel—ovarian cancer	0.000491	0.00243	CcSEcCtD
Procainamide—Flushing—Docetaxel—ovarian cancer	0.000491	0.00243	CcSEcCtD
Procainamide—Cardiac arrest—Epirubicin—ovarian cancer	0.000491	0.00243	CcSEcCtD
Procainamide—Vomiting—Topotecan—ovarian cancer	0.00049	0.00243	CcSEcCtD
Procainamide—Malaise—Paclitaxel—ovarian cancer	0.00049	0.00243	CcSEcCtD
Procainamide—Cardiac failure—Doxorubicin—ovarian cancer	0.000489	0.00242	CcSEcCtD
Procainamide—Lethargy—Doxorubicin—ovarian cancer	0.000487	0.00241	CcSEcCtD
Procainamide—Hypersensitivity—Vinorelbine—ovarian cancer	0.000486	0.00241	CcSEcCtD
Procainamide—CYP2D6—testis—ovarian cancer	0.000481	0.0037	CbGeAlD
Procainamide—Vomiting—Melphalan—ovarian cancer	0.00048	0.00238	CcSEcCtD
Procainamide—Chills—Docetaxel—ovarian cancer	0.000475	0.00235	CcSEcCtD
Procainamide—Asthenia—Vinorelbine—ovarian cancer	0.000473	0.00234	CcSEcCtD
Procainamide—Abdominal pain upper—Epirubicin—ovarian cancer	0.000471	0.00233	CcSEcCtD
Procainamide—Convulsion—Paclitaxel—ovarian cancer	0.000471	0.00233	CcSEcCtD
Procainamide—Pruritus—Vinorelbine—ovarian cancer	0.000467	0.00231	CcSEcCtD
Procainamide—Arthralgia—Paclitaxel—ovarian cancer	0.000463	0.00229	CcSEcCtD
Procainamide—Myalgia—Paclitaxel—ovarian cancer	0.000463	0.00229	CcSEcCtD
Procainamide—Nausea—Topotecan—ovarian cancer	0.000458	0.00227	CcSEcCtD
Procainamide—Discomfort—Paclitaxel—ovarian cancer	0.000457	0.00226	CcSEcCtD
Procainamide—Cardiac arrest—Doxorubicin—ovarian cancer	0.000454	0.00225	CcSEcCtD
Procainamide—Diarrhoea—Vinorelbine—ovarian cancer	0.000451	0.00224	CcSEcCtD
Procainamide—Dysgeusia—Docetaxel—ovarian cancer	0.000451	0.00223	CcSEcCtD
Procainamide—Nausea—Melphalan—ovarian cancer	0.000449	0.00222	CcSEcCtD
Procainamide—Confusional state—Paclitaxel—ovarian cancer	0.000447	0.00222	CcSEcCtD
Procainamide—Eosinophilia—Epirubicin—ovarian cancer	0.000442	0.00219	CcSEcCtD
Procainamide—Shock—Paclitaxel—ovarian cancer	0.000437	0.00216	CcSEcCtD
Procainamide—Dizziness—Vinorelbine—ovarian cancer	0.000436	0.00216	CcSEcCtD
Procainamide—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000436	0.00216	CcSEcCtD
Procainamide—Thrombocytopenia—Paclitaxel—ovarian cancer	0.000434	0.00215	CcSEcCtD
Procainamide—Anorexia—Paclitaxel—ovarian cancer	0.000423	0.00209	CcSEcCtD
Procainamide—Vomiting—Vinorelbine—ovarian cancer	0.000419	0.00208	CcSEcCtD
Procainamide—Neutropenia—Epirubicin—ovarian cancer	0.000417	0.00207	CcSEcCtD
Procainamide—Hypotension—Paclitaxel—ovarian cancer	0.000415	0.00205	CcSEcCtD
Procainamide—Eosinophilia—Doxorubicin—ovarian cancer	0.000409	0.00202	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000404	0.002	CcSEcCtD
Procainamide—Convulsion—Docetaxel—ovarian cancer	0.000399	0.00198	CcSEcCtD
Procainamide—Arthralgia—Docetaxel—ovarian cancer	0.000392	0.00194	CcSEcCtD
Procainamide—Myalgia—Docetaxel—ovarian cancer	0.000392	0.00194	CcSEcCtD
Procainamide—Nausea—Vinorelbine—ovarian cancer	0.000392	0.00194	CcSEcCtD
Procainamide—Renal failure—Epirubicin—ovarian cancer	0.000391	0.00194	CcSEcCtD
Procainamide—Neutropenia—Doxorubicin—ovarian cancer	0.000386	0.00191	CcSEcCtD
Procainamide—Decreased appetite—Paclitaxel—ovarian cancer	0.000386	0.00191	CcSEcCtD
Procainamide—Confusional state—Docetaxel—ovarian cancer	0.000379	0.00188	CcSEcCtD
Procainamide—Agranulocytosis—Epirubicin—ovarian cancer	0.000371	0.00184	CcSEcCtD
Procainamide—Shock—Docetaxel—ovarian cancer	0.00037	0.00183	CcSEcCtD
Procainamide—Thrombocytopenia—Docetaxel—ovarian cancer	0.000368	0.00182	CcSEcCtD
Procainamide—Feeling abnormal—Paclitaxel—ovarian cancer	0.000366	0.00181	CcSEcCtD
Procainamide—Benzocaine—ABCB1—ovarian cancer	0.000364	0.0316	CrCbGaD
Procainamide—Bradycardia—Epirubicin—ovarian cancer	0.000364	0.0018	CcSEcCtD
Procainamide—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000363	0.0018	CcSEcCtD
Procainamide—Renal failure—Doxorubicin—ovarian cancer	0.000362	0.00179	CcSEcCtD
Procainamide—Anorexia—Docetaxel—ovarian cancer	0.000359	0.00178	CcSEcCtD
Procainamide—Urticaria—Paclitaxel—ovarian cancer	0.000353	0.00175	CcSEcCtD
Procainamide—Hypotension—Docetaxel—ovarian cancer	0.000351	0.00174	CcSEcCtD
Procainamide—Abdominal pain—Paclitaxel—ovarian cancer	0.000351	0.00174	CcSEcCtD
Procainamide—Body temperature increased—Paclitaxel—ovarian cancer	0.000351	0.00174	CcSEcCtD
Procainamide—Agranulocytosis—Doxorubicin—ovarian cancer	0.000343	0.0017	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000343	0.0017	CcSEcCtD
Procainamide—Bradycardia—Doxorubicin—ovarian cancer	0.000336	0.00167	CcSEcCtD
Procainamide—Flushing—Epirubicin—ovarian cancer	0.000331	0.00164	CcSEcCtD
Procainamide—Cardiac disorder—Epirubicin—ovarian cancer	0.000331	0.00164	CcSEcCtD
Procainamide—Decreased appetite—Docetaxel—ovarian cancer	0.000327	0.00162	CcSEcCtD
Procainamide—Hypersensitivity—Paclitaxel—ovarian cancer	0.000327	0.00162	CcSEcCtD
Procainamide—Chills—Epirubicin—ovarian cancer	0.00032	0.00159	CcSEcCtD
Procainamide—Asthenia—Paclitaxel—ovarian cancer	0.000318	0.00158	CcSEcCtD
Procainamide—Pruritus—Paclitaxel—ovarian cancer	0.000314	0.00155	CcSEcCtD
Procainamide—Feeling abnormal—Docetaxel—ovarian cancer	0.00031	0.00153	CcSEcCtD
Procainamide—Probenecid—ABCB1—ovarian cancer	0.000308	0.0268	CrCbGaD
Procainamide—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000308	0.00152	CcSEcCtD
Procainamide—Cardiac disorder—Doxorubicin—ovarian cancer	0.000307	0.00152	CcSEcCtD
Procainamide—Flushing—Doxorubicin—ovarian cancer	0.000307	0.00152	CcSEcCtD
Procainamide—Dysgeusia—Epirubicin—ovarian cancer	0.000304	0.00151	CcSEcCtD
Procainamide—Aminohippurate—ABCB1—ovarian cancer	0.000304	0.0265	CrCbGaD
Procainamide—Diarrhoea—Paclitaxel—ovarian cancer	0.000304	0.0015	CcSEcCtD
Procainamide—Abdominal pain—Docetaxel—ovarian cancer	0.000297	0.00147	CcSEcCtD
Procainamide—Body temperature increased—Docetaxel—ovarian cancer	0.000297	0.00147	CcSEcCtD
Procainamide—Lidocaine—ABCB1—ovarian cancer	0.000297	0.0258	CrCbGaD
Procainamide—Chills—Doxorubicin—ovarian cancer	0.000296	0.00147	CcSEcCtD
Procainamide—Dizziness—Paclitaxel—ovarian cancer	0.000293	0.00145	CcSEcCtD
Procainamide—Ill-defined disorder—Epirubicin—ovarian cancer	0.000288	0.00143	CcSEcCtD
Procainamide—Vomiting—Paclitaxel—ovarian cancer	0.000282	0.0014	CcSEcCtD
Procainamide—Dysgeusia—Doxorubicin—ovarian cancer	0.000282	0.00139	CcSEcCtD
Procainamide—Malaise—Epirubicin—ovarian cancer	0.00028	0.00139	CcSEcCtD
Procainamide—Hypersensitivity—Docetaxel—ovarian cancer	0.000277	0.00137	CcSEcCtD
Procainamide—Asthenia—Docetaxel—ovarian cancer	0.00027	0.00134	CcSEcCtD
Procainamide—Convulsion—Epirubicin—ovarian cancer	0.000269	0.00133	CcSEcCtD
Procainamide—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000267	0.00132	CcSEcCtD
Procainamide—Pruritus—Docetaxel—ovarian cancer	0.000266	0.00132	CcSEcCtD
Procainamide—Arthralgia—Epirubicin—ovarian cancer	0.000265	0.00131	CcSEcCtD
Procainamide—Myalgia—Epirubicin—ovarian cancer	0.000265	0.00131	CcSEcCtD
Procainamide—Nausea—Paclitaxel—ovarian cancer	0.000264	0.00131	CcSEcCtD
Procainamide—Discomfort—Epirubicin—ovarian cancer	0.000261	0.00129	CcSEcCtD
Procainamide—Malaise—Doxorubicin—ovarian cancer	0.000259	0.00128	CcSEcCtD
Procainamide—Diarrhoea—Docetaxel—ovarian cancer	0.000257	0.00127	CcSEcCtD
Procainamide—Confusional state—Epirubicin—ovarian cancer	0.000256	0.00127	CcSEcCtD
Procainamide—Shock—Epirubicin—ovarian cancer	0.00025	0.00124	CcSEcCtD
Procainamide—Convulsion—Doxorubicin—ovarian cancer	0.000249	0.00123	CcSEcCtD
Procainamide—Dizziness—Docetaxel—ovarian cancer	0.000249	0.00123	CcSEcCtD
Procainamide—Thrombocytopenia—Epirubicin—ovarian cancer	0.000248	0.00123	CcSEcCtD
Procainamide—Arthralgia—Doxorubicin—ovarian cancer	0.000245	0.00121	CcSEcCtD
Procainamide—Myalgia—Doxorubicin—ovarian cancer	0.000245	0.00121	CcSEcCtD
Procainamide—Sunitinib—ABCB1—ovarian cancer	0.000243	0.0211	CrCbGaD
Procainamide—Discomfort—Doxorubicin—ovarian cancer	0.000242	0.0012	CcSEcCtD
Procainamide—Anorexia—Epirubicin—ovarian cancer	0.000242	0.0012	CcSEcCtD
Procainamide—Vomiting—Docetaxel—ovarian cancer	0.000239	0.00118	CcSEcCtD
Procainamide—Hypotension—Epirubicin—ovarian cancer	0.000237	0.00117	CcSEcCtD
Procainamide—Confusional state—Doxorubicin—ovarian cancer	0.000237	0.00117	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000231	0.00114	CcSEcCtD
Procainamide—Shock—Doxorubicin—ovarian cancer	0.000231	0.00114	CcSEcCtD
Procainamide—Thrombocytopenia—Doxorubicin—ovarian cancer	0.00023	0.00114	CcSEcCtD
Procainamide—Anorexia—Doxorubicin—ovarian cancer	0.000224	0.00111	CcSEcCtD
Procainamide—Nausea—Docetaxel—ovarian cancer	0.000223	0.00111	CcSEcCtD
Procainamide—Decreased appetite—Epirubicin—ovarian cancer	0.000221	0.00109	CcSEcCtD
Procainamide—Hypotension—Doxorubicin—ovarian cancer	0.000219	0.00109	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000214	0.00106	CcSEcCtD
Procainamide—Feeling abnormal—Epirubicin—ovarian cancer	0.000209	0.00104	CcSEcCtD
Procainamide—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000207	0.00103	CcSEcCtD
Procainamide—Decreased appetite—Doxorubicin—ovarian cancer	0.000204	0.00101	CcSEcCtD
Procainamide—Urticaria—Epirubicin—ovarian cancer	0.000202	0.000998	CcSEcCtD
Procainamide—Abdominal pain—Epirubicin—ovarian cancer	0.000201	0.000993	CcSEcCtD
Procainamide—Body temperature increased—Epirubicin—ovarian cancer	0.000201	0.000993	CcSEcCtD
Procainamide—Feeling abnormal—Doxorubicin—ovarian cancer	0.000193	0.000958	CcSEcCtD
Procainamide—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000192	0.00095	CcSEcCtD
Procainamide—Hypersensitivity—Epirubicin—ovarian cancer	0.000187	0.000926	CcSEcCtD
Procainamide—Urticaria—Doxorubicin—ovarian cancer	0.000186	0.000923	CcSEcCtD
Procainamide—Abdominal pain—Doxorubicin—ovarian cancer	0.000186	0.000919	CcSEcCtD
Procainamide—Body temperature increased—Doxorubicin—ovarian cancer	0.000186	0.000919	CcSEcCtD
Procainamide—Asthenia—Epirubicin—ovarian cancer	0.000182	0.000901	CcSEcCtD
Procainamide—Pruritus—Epirubicin—ovarian cancer	0.000179	0.000889	CcSEcCtD
Procainamide—Diarrhoea—Epirubicin—ovarian cancer	0.000174	0.00086	CcSEcCtD
Procainamide—Hypersensitivity—Doxorubicin—ovarian cancer	0.000173	0.000856	CcSEcCtD
Procainamide—Asthenia—Doxorubicin—ovarian cancer	0.000168	0.000834	CcSEcCtD
Procainamide—Dizziness—Epirubicin—ovarian cancer	0.000168	0.000831	CcSEcCtD
Procainamide—Pruritus—Doxorubicin—ovarian cancer	0.000166	0.000822	CcSEcCtD
Procainamide—Vomiting—Epirubicin—ovarian cancer	0.000161	0.000799	CcSEcCtD
Procainamide—Diarrhoea—Doxorubicin—ovarian cancer	0.000161	0.000795	CcSEcCtD
Procainamide—Dizziness—Doxorubicin—ovarian cancer	0.000155	0.000769	CcSEcCtD
Procainamide—Nausea—Epirubicin—ovarian cancer	0.000151	0.000746	CcSEcCtD
Procainamide—Vomiting—Doxorubicin—ovarian cancer	0.000149	0.000739	CcSEcCtD
Procainamide—Nausea—Doxorubicin—ovarian cancer	0.000139	0.00069	CcSEcCtD
Procainamide—SCN1A—Developmental Biology—EGFR—ovarian cancer	4.41e-05	0.000472	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—MAPK3—ovarian cancer	4.39e-05	0.000469	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PPP1CC—ovarian cancer	4.37e-05	0.000467	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—BRIP1—ovarian cancer	4.37e-05	0.000467	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—PIK3CA—ovarian cancer	4.37e-05	0.000467	CbGpPWpGaD
Procainamide—SCN8A—Developmental Biology—AKT1—ovarian cancer	4.37e-05	0.000467	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—MAPK1—ovarian cancer	4.35e-05	0.000465	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—EGFR—ovarian cancer	4.35e-05	0.000465	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—MAPK1—ovarian cancer	4.33e-05	0.000463	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—KRAS—ovarian cancer	4.32e-05	0.000462	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—KRAS—ovarian cancer	4.32e-05	0.000462	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.29e-05	0.000459	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—NME2—ovarian cancer	4.29e-05	0.000458	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—TP53—ovarian cancer	4.23e-05	0.000452	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—MAPK1—ovarian cancer	4.17e-05	0.000446	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—EGFR—ovarian cancer	4.17e-05	0.000446	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—KRAS—ovarian cancer	4.17e-05	0.000446	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—KRAS—ovarian cancer	4.17e-05	0.000446	CbGpPWpGaD
Procainamide—SLC22A2—Transmembrane transport of small molecules—ABCB1—ovarian cancer	4.11e-05	0.000439	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—KRAS—ovarian cancer	4.11e-05	0.000439	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—FASN—ovarian cancer	4.09e-05	0.000437	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—SLC5A5—ovarian cancer	4.02e-05	0.00043	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—HRAS—ovarian cancer	4e-05	0.000427	CbGpPWpGaD
Procainamide—CHRM2—G alpha (i) signalling events—CXCL8—ovarian cancer	3.97e-05	0.000424	CbGpPWpGaD
Procainamide—ACHE—Metabolism—YAP1—ovarian cancer	3.95e-05	0.000422	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—KRAS—ovarian cancer	3.94e-05	0.000422	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—CTNNB1—ovarian cancer	3.92e-05	0.000419	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.91e-05	0.000418	CbGpPWpGaD
Procainamide—ACHE—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.9e-05	0.000417	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—SLC2A1—ovarian cancer	3.89e-05	0.000415	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.87e-05	0.000414	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MMP9—ovarian cancer	3.84e-05	0.00041	CbGpPWpGaD
Procainamide—SLC22A1—Transmembrane transport of small molecules—ABCB1—ovarian cancer	3.83e-05	0.000409	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	3.83e-05	0.000409	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—IL6—ovarian cancer	3.83e-05	0.000409	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—HRAS—ovarian cancer	3.82e-05	0.000409	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CYP1B1—ovarian cancer	3.72e-05	0.000398	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—MAPK1—ovarian cancer	3.72e-05	0.000398	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—HRAS—ovarian cancer	3.67e-05	0.000393	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—HRAS—ovarian cancer	3.67e-05	0.000393	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—IL6—ovarian cancer	3.66e-05	0.000391	CbGpPWpGaD
Procainamide—CHRM2—Regulation of Actin Cytoskeleton—PIK3CA—ovarian cancer	3.62e-05	0.000387	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—MAPK1—ovarian cancer	3.61e-05	0.000385	CbGpPWpGaD
Procainamide—ACHE—Integrated Pancreatic Cancer Pathway—AKT1—ovarian cancer	3.57e-05	0.000382	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—DOK1—ovarian cancer	3.56e-05	0.00038	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—HRAS—ovarian cancer	3.54e-05	0.000379	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—HRAS—ovarian cancer	3.54e-05	0.000379	CbGpPWpGaD
Procainamide—SCN9A—Developmental Biology—AKT1—ovarian cancer	3.53e-05	0.000377	CbGpPWpGaD
Procainamide—BCHE—Metabolism—YAP1—ovarian cancer	3.52e-05	0.000377	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—IL6—ovarian cancer	3.52e-05	0.000376	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—IL6—ovarian cancer	3.52e-05	0.000376	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—HRAS—ovarian cancer	3.49e-05	0.000373	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	3.49e-05	0.000373	CbGpPWpGaD
Procainamide—BCHE—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.48e-05	0.000372	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—VEGFA—ovarian cancer	3.45e-05	0.000368	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.44e-05	0.000367	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—STAT3—ovarian cancer	3.41e-05	0.000365	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—NRAS—ovarian cancer	3.4e-05	0.000364	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—IL6—ovarian cancer	3.39e-05	0.000363	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—IL6—ovarian cancer	3.39e-05	0.000363	CbGpPWpGaD
Procainamide—SCN3A—Developmental Biology—AKT1—ovarian cancer	3.38e-05	0.000361	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PPP1CC—ovarian cancer	3.34e-05	0.000358	CbGpPWpGaD
Procainamide—SCN5A—Axon guidance—IL6—ovarian cancer	3.34e-05	0.000357	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—MAPK1—ovarian cancer	3.32e-05	0.000355	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PPP2R1A—ovarian cancer	3.3e-05	0.000353	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MAPK3—ovarian cancer	3.26e-05	0.000349	CbGpPWpGaD
Procainamide—SCN4A—Developmental Biology—AKT1—ovarian cancer	3.24e-05	0.000347	CbGpPWpGaD
Procainamide—SCN2A—Developmental Biology—AKT1—ovarian cancer	3.24e-05	0.000347	CbGpPWpGaD
Procainamide—ACHE—Metabolism—FASN—ovarian cancer	3.22e-05	0.000344	CbGpPWpGaD
Procainamide—ACHE—Metabolism—SLC5A5—ovarian cancer	3.17e-05	0.000338	CbGpPWpGaD
Procainamide—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	3.15e-05	0.000337	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—YAP1—ovarian cancer	3.15e-05	0.000336	CbGpPWpGaD
Procainamide—SCN10A—Developmental Biology—AKT1—ovarian cancer	3.13e-05	0.000334	CbGpPWpGaD
Procainamide—SCN1A—Developmental Biology—AKT1—ovarian cancer	3.13e-05	0.000334	CbGpPWpGaD
Procainamide—SLC22A2—Transmission across Chemical Synapses—HRAS—ovarian cancer	3.11e-05	0.000332	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—MAPK1—ovarian cancer	3.1e-05	0.000332	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—EGFR—ovarian cancer	3.1e-05	0.000332	CbGpPWpGaD
Procainamide—CHRM2—SIDS Susceptibility Pathways—IL6—ovarian cancer	3.09e-05	0.000331	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—MAPK3—ovarian cancer	3.08e-05	0.000329	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—ABCB1—ovarian cancer	3.07e-05	0.000328	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.07e-05	0.000328	CbGpPWpGaD
Procainamide—ACHE—Metabolism—SLC2A1—ovarian cancer	3.06e-05	0.000327	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—TYMS—ovarian cancer	3.01e-05	0.000322	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.99e-05	0.00032	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—MYC—ovarian cancer	2.99e-05	0.00032	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—MMP2—ovarian cancer	2.99e-05	0.00032	CbGpPWpGaD
Procainamide—ACHE—Neuronal System—HRAS—ovarian cancer	2.99e-05	0.000319	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—MAPK1—ovarian cancer	2.96e-05	0.000317	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—YAP1—ovarian cancer	2.93e-05	0.000313	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CYP1B1—ovarian cancer	2.93e-05	0.000313	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—KRAS—ovarian cancer	2.93e-05	0.000313	CbGpPWpGaD
Procainamide—SLC22A1—Transmission across Chemical Synapses—HRAS—ovarian cancer	2.9e-05	0.000309	CbGpPWpGaD
Procainamide—BCHE—Metabolism—FASN—ovarian cancer	2.87e-05	0.000307	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SLC5A5—ovarian cancer	2.83e-05	0.000302	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—MAPK1—ovarian cancer	2.76e-05	0.000295	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYTB—ovarian cancer	2.76e-05	0.000295	CbGpPWpGaD
Procainamide—BCHE—Metabolism—SLC2A1—ovarian cancer	2.73e-05	0.000292	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	2.67e-05	0.000286	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—MMP2—ovarian cancer	2.67e-05	0.000285	CbGpPWpGaD
Procainamide—BCHE—Neuronal System—HRAS—ovarian cancer	2.66e-05	0.000285	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CYP1B1—ovarian cancer	2.62e-05	0.00028	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PPP2R1A—ovarian cancer	2.6e-05	0.000278	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.59e-05	0.000277	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—FASN—ovarian cancer	2.57e-05	0.000274	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HDAC6—ovarian cancer	2.53e-05	0.000271	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SLC5A5—ovarian cancer	2.52e-05	0.00027	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PPP2R1A—ovarian cancer	2.5e-05	0.000267	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—HRAS—ovarian cancer	2.49e-05	0.000266	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—CXCL8—ovarian cancer	2.49e-05	0.000266	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—SLC2A1—ovarian cancer	2.44e-05	0.00026	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—CAV1—ovarian cancer	2.43e-05	0.000259	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—BRIP1—ovarian cancer	2.42e-05	0.000258	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PPP1CC—ovarian cancer	2.42e-05	0.000258	CbGpPWpGaD
Procainamide—ACHE—Metabolism—ABCB1—ovarian cancer	2.41e-05	0.000258	CbGpPWpGaD
Procainamide—CHRM2—GPCR ligand binding—CXCL8—ovarian cancer	2.4e-05	0.000257	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—FASN—ovarian cancer	2.39e-05	0.000256	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—IL6—ovarian cancer	2.38e-05	0.000255	CbGpPWpGaD
Procainamide—SLC22A2—Neuronal System—HRAS—ovarian cancer	2.38e-05	0.000254	CbGpPWpGaD
Procainamide—ACHE—Metabolism—TYMS—ovarian cancer	2.37e-05	0.000253	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SLC5A5—ovarian cancer	2.35e-05	0.000251	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CYP1B1—ovarian cancer	2.34e-05	0.00025	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PPP2R1A—ovarian cancer	2.32e-05	0.000248	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.31e-05	0.000247	CbGpPWpGaD
Procainamide—ACHE—Metabolism of proteins—CTNNB1—ovarian cancer	2.29e-05	0.000245	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—SLC2A1—ovarian cancer	2.27e-05	0.000243	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—YAP1—ovarian cancer	2.24e-05	0.00024	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—CXCL8—ovarian cancer	2.22e-05	0.000237	CbGpPWpGaD
Procainamide—SLC22A1—Neuronal System—HRAS—ovarian cancer	2.22e-05	0.000237	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CG—ovarian cancer	2.21e-05	0.000236	CbGpPWpGaD
Procainamide—SCN5A—Developmental Biology—AKT1—ovarian cancer	2.2e-05	0.000235	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—XIAP—ovarian cancer	2.2e-05	0.000235	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CYP1B1—ovarian cancer	2.18e-05	0.000233	CbGpPWpGaD
Procainamide—BCHE—Metabolism—ABCB1—ovarian cancer	2.15e-05	0.00023	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—SMARCA4—ovarian cancer	2.14e-05	0.000229	CbGpPWpGaD
Procainamide—BCHE—Metabolism—TYMS—ovarian cancer	2.12e-05	0.000226	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EREG—ovarian cancer	2.09e-05	0.000223	CbGpPWpGaD
Procainamide—DNMT1—Gene Expression—AKT1—ovarian cancer	2.08e-05	0.000222	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PPP2R1A—ovarian cancer	2.07e-05	0.000221	CbGpPWpGaD
Procainamide—BCHE—Metabolism of proteins—CTNNB1—ovarian cancer	2.05e-05	0.000219	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PGR—ovarian cancer	1.96e-05	0.000209	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CD—ovarian cancer	1.94e-05	0.000208	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PPP2R1A—ovarian cancer	1.93e-05	0.000206	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—ABCB1—ovarian cancer	1.92e-05	0.000206	CbGpPWpGaD
Procainamide—ACHE—Metabolism—CAV1—ovarian cancer	1.91e-05	0.000204	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—TYMS—ovarian cancer	1.89e-05	0.000202	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CG—ovarian cancer	1.84e-05	0.000197	CbGpPWpGaD
Procainamide—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.83e-05	0.000195	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PARP1—ovarian cancer	1.82e-05	0.000195	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—ABCB1—ovarian cancer	1.79e-05	0.000192	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—TYMS—ovarian cancer	1.76e-05	0.000188	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6ST—ovarian cancer	1.74e-05	0.000186	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CG—ovarian cancer	1.74e-05	0.000186	CbGpPWpGaD
Procainamide—BCHE—Metabolism—CAV1—ovarian cancer	1.7e-05	0.000182	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CB—ovarian cancer	1.69e-05	0.000181	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CG—ovarian cancer	1.67e-05	0.000179	CbGpPWpGaD
Procainamide—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.63e-05	0.000174	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CD—ovarian cancer	1.62e-05	0.000173	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—YAP1—ovarian cancer	1.62e-05	0.000173	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CG—ovarian cancer	1.55e-05	0.000166	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CD—ovarian cancer	1.53e-05	0.000164	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—CAV1—ovarian cancer	1.52e-05	0.000163	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PPP2R1A—ovarian cancer	1.48e-05	0.000158	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CD—ovarian cancer	1.47e-05	0.000157	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PTEN—ovarian cancer	1.46e-05	0.000156	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—CAV1—ovarian cancer	1.42e-05	0.000152	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CB—ovarian cancer	1.41e-05	0.000151	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CG—ovarian cancer	1.39e-05	0.000148	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CD—ovarian cancer	1.37e-05	0.000146	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—CXCL8—ovarian cancer	1.36e-05	0.000145	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CB—ovarian cancer	1.33e-05	0.000143	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—FASN—ovarian cancer	1.32e-05	0.000141	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC5A5—ovarian cancer	1.3e-05	0.000139	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—IL2—ovarian cancer	1.3e-05	0.000139	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CG—ovarian cancer	1.29e-05	0.000138	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CB—ovarian cancer	1.28e-05	0.000137	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—SLC2A1—ovarian cancer	1.25e-05	0.000134	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—CXCL8—ovarian cancer	1.23e-05	0.000132	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CD—ovarian cancer	1.22e-05	0.00013	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CYP1B1—ovarian cancer	1.2e-05	0.000129	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CB—ovarian cancer	1.19e-05	0.000127	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL2—ovarian cancer	1.18e-05	0.000126	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TERT—ovarian cancer	1.17e-05	0.000125	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PTEN—ovarian cancer	1.15e-05	0.000123	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CD—ovarian cancer	1.14e-05	0.000121	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CAV1—ovarian cancer	1.09e-05	0.000116	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	1.07e-05	0.000114	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CB—ovarian cancer	1.06e-05	0.000114	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ESR1—ovarian cancer	1.05e-05	0.000112	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—PIK3CA—ovarian cancer	1.03e-05	0.00011	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6ST—ovarian cancer	1.03e-05	0.00011	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PTEN—ovarian cancer	1.03e-05	0.00011	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CB—ovarian cancer	9.9e-06	0.000106	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—ABCB1—ovarian cancer	9.9e-06	0.000106	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CG—ovarian cancer	9.89e-06	0.000106	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—APC—ovarian cancer	9.89e-06	0.000106	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—NRAS—ovarian cancer	9.89e-06	0.000106	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—TYMS—ovarian cancer	9.73e-06	0.000104	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MAPK3—ovarian cancer	9.47e-06	0.000101	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PTEN—ovarian cancer	9.18e-06	9.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—MAPK1—ovarian cancer	9.01e-06	9.63e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—EGFR—ovarian cancer	9.01e-06	9.63e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CD—ovarian cancer	8.69e-06	9.29e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—PIK3CA—ovarian cancer	8.61e-06	9.2e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PTEN—ovarian cancer	8.56e-06	9.15e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—KRAS—ovarian cancer	8.51e-06	9.1e-05	CbGpPWpGaD
Procainamide—SLC22A3—Metabolism—AKT1—ovarian cancer	8.44e-06	9.02e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—PIK3CA—ovarian cancer	8.13e-06	8.69e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—CAV1—ovarian cancer	7.84e-06	8.38e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—PIK3CA—ovarian cancer	7.82e-06	8.36e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—ERBB2—ovarian cancer	7.68e-06	8.21e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CB—ovarian cancer	7.58e-06	8.1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MTOR—ovarian cancer	7.58e-06	8.1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CXCL8—ovarian cancer	7.28e-06	7.78e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—PIK3CA—ovarian cancer	7.25e-06	7.75e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—HRAS—ovarian cancer	7.23e-06	7.73e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CG—ovarian cancer	7.14e-06	7.63e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CDKN1B—ovarian cancer	7.11e-06	7.6e-05	CbGpPWpGaD
Procainamide—CHRM2—GPCR downstream signaling—AKT1—ovarian cancer	7.03e-06	7.52e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CASP3—ovarian cancer	6.97e-06	7.45e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL2—ovarian cancer	6.96e-06	7.44e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—IL6—ovarian cancer	6.92e-06	7.4e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CCND1—ovarian cancer	6.78e-06	7.25e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—CTNNB1—ovarian cancer	6.72e-06	7.18e-05	CbGpPWpGaD
Procainamide—ACHE—Metabolism—AKT1—ovarian cancer	6.64e-06	7.1e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MMP9—ovarian cancer	6.58e-06	7.04e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PTEN—ovarian cancer	6.55e-06	7e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—PIK3CA—ovarian cancer	6.48e-06	6.92e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling by GPCR—AKT1—ovarian cancer	6.39e-06	6.83e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CD—ovarian cancer	6.28e-06	6.71e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—PIK3CA—ovarian cancer	6.04e-06	6.45e-05	CbGpPWpGaD
Procainamide—BCHE—Metabolism—AKT1—ovarian cancer	5.93e-06	6.33e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—VEGFA—ovarian cancer	5.91e-06	6.32e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—STAT3—ovarian cancer	5.85e-06	6.26e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—NRAS—ovarian cancer	5.84e-06	6.24e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK3—ovarian cancer	5.59e-06	5.98e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CB—ovarian cancer	5.47e-06	5.85e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MYC—ovarian cancer	5.44e-06	5.82e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—MAPK1—ovarian cancer	5.32e-06	5.69e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—EGFR—ovarian cancer	5.32e-06	5.69e-05	CbGpPWpGaD
Procainamide—SLC22A2—Metabolism—AKT1—ovarian cancer	5.29e-06	5.66e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—KRAS—ovarian cancer	5.03e-06	5.37e-05	CbGpPWpGaD
Procainamide—SLC22A1—Metabolism—AKT1—ovarian cancer	4.93e-06	5.27e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PTEN—ovarian cancer	4.73e-06	5.05e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—PIK3CA—ovarian cancer	4.62e-06	4.94e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—TP53—ovarian cancer	4.47e-06	4.78e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—HRAS—ovarian cancer	4.27e-06	4.57e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—IL6—ovarian cancer	4.09e-06	4.37e-05	CbGpPWpGaD
Procainamide—CHRM2—Signaling Pathways—AKT1—ovarian cancer	3.77e-06	4.03e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—PIK3CA—ovarian cancer	3.33e-06	3.56e-05	CbGpPWpGaD
Procainamide—CYP2D6—Metabolism—AKT1—ovarian cancer	2.72e-06	2.91e-05	CbGpPWpGaD
